CN101606923B - Stable controlled-release rasagiline transdermal patch and preparation method thereof - Google Patents
Stable controlled-release rasagiline transdermal patch and preparation method thereof Download PDFInfo
- Publication number
- CN101606923B CN101606923B CN2008100698501A CN200810069850A CN101606923B CN 101606923 B CN101606923 B CN 101606923B CN 2008100698501 A CN2008100698501 A CN 2008100698501A CN 200810069850 A CN200810069850 A CN 200810069850A CN 101606923 B CN101606923 B CN 101606923B
- Authority
- CN
- China
- Prior art keywords
- rasagiline
- acid
- transdermal patch
- paster
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
The invention relates to rasagiline for treating or preventing nervous system diseases and a transdermal patch of a pharmaceutically acceptable slat of rasagiline. The transdermal patch comprises the rasagiline or the pharmaceutically acceptable slat of rasagiline and at least one hydrophilic polymer substrate. And the PH value of the patch ranges from 3.5 to 6.5. The patch has the characteristics of excellent stability and good control over transdermal release of the rasagiline.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, be specifically related to be used for the treatment of or prevent the rasagiline (rasagiline) of nervous system disease and the transdermal drug paster of pharmaceutically acceptable salt thereof, contain at least a hydrophilic polymeric matrix, the pH value of this paster is not more than 7.0, especially is being not less than 3.0 to being not more than between 6.5.
Technical background
Rasagiline (rasagiline) is a kind of selectivity monoamine oxidase B inhibitors, is used for the treatment of central nervous system disease, such as parkinson (PD), depression etc., goes on the market in Europe.The chemical structural formula of rasagiline is as follows.
Parkinson is that the dopaminergic nerve in the nerve centre is degenerated the result that the neurotransmitter dopamine burst size reduces.Because the deficiency of dopamine mediator burst size, cause patient's muscle control imbalance, initiation is trembled, muscular rigidity, feel nervous from head to foot, joint motion is dumb, even stand up all difficulty, be slow in action slow in one's movements, clumsy, activity is inharmonious, the severe patient symptoms such as very difficult, abnormal posture of standing, walk all.
The main purpose of Drug therapy parkinson disease (PD) all is to improve directly or indirectly IC DOPAMINE CONTENT IN RABBIT.The main medicine for the treatment of Parkinson's disease has levodopa, dopamine-receptor stimulant, amantadine, anticholinergic agents, anticholinergic agents etc.In the later stage sixties, levodopa (L-dopa) begins to be applied in the parkinsonian treatment as the alternative medicine of neurotransmitter dopamine, remains so far main medicine.Owing to levodopa rapid decarboxylation outside brain is transformed into dopamine, cause a large amount of wastes of levodopa and the frequent occurrence of untoward reaction.Therefore, levodopa usually uses jointly with decarboxylase inhibitor, and the raising levodopa is by the ability of brain blood barrier.Treating parkinsonian another medicine classification is dopamine-receptor stimulant (dopamine agonist), comprises bromocriptine parlodel and pergolide mesylate.Promote the content of dopamine in brain by the enzyme that suppresses the decomposition dopamine.Dopamine agonist has the long half-life, can directly act on receptor, can reduce administration number of times and the dosage of levodopa.
Rasagiline is irreversible selectivity monoamine oxidase-B (MAOB) inhibitor, and effectiveness (Arch Neurol, 2004 that rasagiline is treated early stage PD have been investigated in a double blind random clinical research; 61:561～566).The early stage PD patient of 404 examples is included in research in, and the patient accepts rasagiline (1mg/d or 2mg/d) treatment 1 year, or accepts first 6 months rasagilines and take 6 months placebo again.Main evaluation index changes for the score value of unified parkinson disease comprehensive grading scales (UPDRS).The result shows, 371 routine patients have finished clinical research, annual patient with the treatment of 2mg/d rasagiline hangs down 2.29 units than the rear average UPDRS score value of accepting the patient of placebo treatment in 6 months, accepts low 1.82 units of average UPDRS score value of the patient of rasagiline treatment than annual 1mg/d.Researcher is summed up, and patient's the deterioration degree of accepting rasagiline (1mg/d or 2mg/d) treatment the whole year is low than placebo group.Although rasagiline and other antiparkinsonian drug phase are seemingly, the incidence rate of this product toxic and side effects (mainly comprise insomnia, feel sick and hallucination) is lower.
Because the rasagiline drug effect is very strong, and during oral administration, feed but can make the blood peak concentration of drug descend 60%, adds the Parkinsonian handicapped, oral administration difficulty is so make at least two days to rasagiline once or the longer time is administered once is necessary via the skin dispenser.Though rasagiline is selectivity monoamine oxidase-B (MAOB) inhibitor in addition, but when blood drug level is large, can suppress simultaneously MAO-A, MAO-B, produce so-called " cheese reaction ": when both taking irreversible nonselective medicine, if the patient takes medicine or the food that contains tyramine or dopamine simultaneously, can cause hypertensive crisis.Because contain a large amount of tyramine compositions in the ripe cheese, so this reaction is called " cheese reaction ".Have report to show: when the oral rasagiline 10mg/ of patient days and and during the levodopa coupling, can be because of the cardiovascular adverse effects such as hypertension and position hypertension therapy discontinued.These untoward reaction may be relevant with the non-selective inhibition of MAO-A, MAO-B.Rasagiline transdermal patch absorbs gentle, can Avoids or reduces " cheese reaction ".In case and the patient also can tear paster off immediately because " cheese reaction " do not feel well, and avoids producing more serious consequence.
Described a kind of system via skin treating in US2004013620, active component has wherein comprised rasagiline, it is characterized in that using the transdermal penetration promoter that has with the following formula structure:
It is desirable especially that this transdermal penetration promoter sees through effect to the percutaneous that promotes rasagiline, and what adopt is the spraying Transdermal absorption, administration inconvenience.Seek a kind of medication convenient, and the better patch of transdermal effect, for the patient provides more selection necessary.
A kind of rasagiline transdermal patche that is used for the treatment of or prevents nervous system disease has been described in CN101032474, the pH value of paster remains on alkaline range (greater than 7.0) among the embodiment, although can obtain good transdermal penetration effect, but research is found under the thimble test condition, medicine stability is bad, may be unfavorable for long term storage, and adopt some that zest solvent such as chloroform are arranged.Therefore, seek a kind of both stablely, can keep again good osmotic effect and better control pharmaceutical release time, and safety, the paster of cleaning is very necessary.
Summary of the invention
The rasagiline transdermal patch that one of purpose of the present invention provides a kind of stable capable of realizing controlled-release to discharge, comprise: the rasagiline of a effective dose and pharmaceutically acceptable salt thereof, at least a hydrophilic polymeric matrix of b, the pH value of this paster of c be not more than 7.0.Preferred pH value is being not less than 3.0 to being not more than between 6.5.This paster can keep the stability of active substance rasagiline and good transdermal effect, is fit to long-term storage, and less to the zest of skin.Be used for the treatment of or prevent nervous system disease, such as parkinson medicine, senile dementia, depression etc.
Rasagiline transdermal patch of the present invention, rasagiline wherein comprises hydrochlorate, mesylate, esilate or sulfate at pharmaceutically acceptable salt, preferred salt hydrochlorate and mesylate, more preferably mesylate.
Rasagiline transdermal patch of the present invention, described hydrophilic polymer substrate, be selected from least a in the following material: polyvinylpyrrolidone and derivant thereof, Polyethylene Glycol and derivant thereof, ethylene-vinyl acetate copolymer and derivant thereof, cellulose and derivant thereof and carbopol and derivant thereof, preferred two kinds of materials wherein, more preferably polyvinylpyrrolidone and derivant thereof and Polyethylene Glycol and derivant thereof, cellulose and derivant thereof and carbopol and derivant thereof.
Above-mentioned rasagiline transdermal patch also further comprises at least a hydrophobic polymeric matrix, and said hydrophobic polymer substrate comprises polyacrylic resin and derivant or silicone and derivant thereof.
Rasagiline transdermal patch of the present invention, as required, can also further add one deck release-controlled film, its membrane material is selected from least a in the following material: polyethylene and derivant thereof, ethylene-vinyl acetate copolymer and derivant thereof, polyurethane and derivant thereof, polrvinyl chloride and derivant thereof, its moist steam permeability are 100 g/ms/day to 3000 g/ms/day.
Rasagiline transdermal patch of the present invention, as required, as when needs are controlled drug release rate by the release area, adopt to add a skim, this film has one at least less than the hole of paster area, the size by control paster area and fenestra recently control drug release rate.
Rasagiline transdermal patch of the present invention also can comprise a kind of PH regulator or buffer in case of necessity, makes the pH value of paster remain on 3.0-6.5.The PH regulator is selected from least a material in the following acidic materials: adipic acid, caproic acid, propanoic acid, benzoic acid, phenylacetic acid, phthalic acid, formic acid, hypophosphorous acid, phosphoric acid, sodium dihydrogen phosphate, potassium dihydrogen phosphate, glacial acetic acid, acetic acid, lactic acid, malic acid, citric acid, hydrochloric acid, sulphuric acid, nitric acid, sulfonic acid, methanesulfonic acid, tartaric acid, succinic acid, boric acid, sorbic acid and silicic acid, preferred hydrochloric acid and methanesulfonic acid, more preferably methanesulfonic acid; Described buffer is selected from least a in the following solution: formates buffer, acetate buffer, phosphate buffer, citrate buffer and phthalate buffer.
Rasagiline transdermal patch of the present invention, in order to improve transdermal effect, also comprise at least a transdermal enhancer, said transdermal enhancer is selected from least a in the following material: ethanol, propylene glycol, oleic acid, oleyl alcohol, linoleic acid, lauryl alcohol, lauric acid, isopropyl myristate and laurocapram.
Another purpose of the present invention also provides a kind of usefulness purposes that parkinson, Alzheimer, depression, hyperkinetic syndrome, restless legs syndrome, multiple sclerosis and withdrawal syndrome were treated or prevented to rasagiline transdermal patche of the present invention.
The percutaneous plaster that contains rasagiline and pharmaceutically acceptable salt thereof of the present invention, wherein rasagiline and the effective dose of pharmaceutically acceptable salt in hypothallus thereof are 0.01mg/cm
2～50mg/cm
2, effective dose is the free alkali in rasagiline.
Sha Jilan transdermal drug paster of the present invention is 1cm via the area of using of skin treating
2～50cm
2
Specifically describe
The invention provides a kind of rasagiline transdermal patch of stable capable of realizing controlled-release release, the rasagiline and the pharmaceutically acceptable salt thereof that comprise effective dose, at least a hydrophilic polymer substrate that contains rasagiline and pharmaceutically acceptable salt thereof, the pH value of this paster is not more than 7.0, preferably is being not less than 3.0 to being not more than between 6.5.The backing layer and the conventional back lining materials that also comprise simultaneously this area routine, and the protective layer that tears off before one deck use.Described inertia supporting layer (backing layer) can be selected diaphragm that film material, ethylene-vinyl acetate copolymer, the Merlon such as paillon foil or polyethylene, polypropylene are composited or non-woven fabrics etc.The diaphragm that protective layer (adherent layer) also can select the film materials such as paillon foil or polyethylene, polypropylene, ethylene-vinyl acetate copolymer or Merlon to be composited also can be selected the smooth ground paper of processing through paraffin or methyl-silicone oil.The solvent that also comprises this area routine in this paster, the preferred water soluble solvent such as methanol, ethanol, propanol, isopropyl alcohol, butanols, amylalcohol, propylene glycol, glycerol, can be selected wherein one or more, or select as required.Also can add transdermal enhancer in order to improve transdermal effect, such as ethanol, propylene glycol, oleic acid, oleyl alcohol, linoleic acid, lauryl alcohol, lauric acid, isopropyl myristate and laurocapram etc., preferred laurocapram.
Rasagiline transdermal patch of the present invention, wherein, rasagiline or its pharmaceutically acceptable salt exist with at least a form in the following form in hypothallus: salt, ionic species, crystallite, amorphous dispersion, microemulsion parcel, submicron emulsion parcel, lipid parcel or micelle parcel.
The pharmaceutically acceptable salt of above-mentioned said rasagiline is hydrochlorate, mesylate, benzene sulfonate, tosilate or sulfate, preferred mesylate.
The inventor finds, under alkali condition, although rasagiline has preferably release rate and transdermal effect, but its stability is not ideal under the thimble test condition, be unfavorable for long-term storage, and under acid condition, be not more than at 7.0 o'clock such as PH, especially but keep stable being not more than 6.5 o'clock rasagilines, therefore, the PH scope of control paster is just particularly important, can add PH regulator or buffer in case of necessity, as when active substance is the rasagiline free alkali, pH value just need to add the PH regulator of acid material greater than 6.5, and perhaps active substance is rasagiline mesilate, but also can be by adding PH regulator or buffer when the substrate that adopts is alkaline matter, perhaps other reason cause paster pH value greater than 6.5 o'clock, also should add the PH regulator, the pH value of paster is remained on is less than or equal to 6.5 scope.Described PH regulator comprises adipic acid, caproic acid, propanoic acid, benzoic acid, phenylacetic acid, phthalic acid, formic acid, hypophosphorous acid, phosphoric acid, sodium dihydrogen phosphate, potassium dihydrogen phosphate, glacial acetic acid, acetic acid, lactic acid, malic acid, citric acid, hydrochloric acid, sulphuric acid, nitric acid, sulfonic acid, methanesulfonic acid, benzenesulfonic acid, p-methyl benzenesulfonic acid, tartaric acid, succinic acid, boric acid, sorbic acid and silicic acid, or acid polymer such as carbopol and derivant (such as card pool nurse) thereof, preferred hydrochloric acid, methanesulfonic acid and p-methyl benzenesulfonic acid; Described buffer is selected from least a in the following solution: formates buffer, acetate buffer, phosphate buffer, citrate buffer and phthalate buffer.Find simultaneously under acid condition, such as PH less than in 6.5 the situation, the salt of rasagiline such as rasagiline mesilate dissolubility in hydrophobic substrate is less, causes the drug loading of substrate low, affects release rate and transdermal effect, and the dissolubility of rasagiline mesilate in hydrophilic substrate is fine, drug loading is high, and drug release is fast, and transdermal effect is good, therefore, selecting hydrophilic substrate is comparatively ideal scheme.
Rasagiline and the pharmaceutically acceptable salt percutaneous plaster thereof of containing of the present invention, wherein rasagiline or its pharmaceutically acceptable salt exist with at least a form in the following form in hypothallus: salt, ionic species, crystallite, amorphous dispersion, microemulsion parcel, submicron emulsion parcel, lipid parcel or micelle parcel.
More common being easy to get of transdermal penetration promoter that rasagiline transdermal patch of the present invention is more used than US2004013620.Compare with CN101032474, more stable, hold time longlyer, prepare easier, safety and environmental protection.
In one embodiment, rasagiline transdermal patch of the present invention, the salt of its rasagiline is preferably its mesylate, at least contain 2 kinds of hydrophilic polymer substrate, these hydrophilic matrixs comprise polyvinylpyrrolidone and derivant thereof, such as polyvinylpyrrolidone K15, polyvinylpyrrolidone K25, PVP K30, polyvinylpyrrolidone K60, PVP K90, crospolyvinylpyrrolidone, vinyl pyrrolidone-Hydroxypropyl methacrylate copolymer, vinylpyrrolidone-vinyl acetate copolymer etc.; Polyethylene Glycol and derivant thereof are such as Macrogol 200, Liquid Macrogol, PEG400, Macrogol 600, cetomacrogol 1000, polyethylene glycol 1500, Macrogol 2000, Macrogol 3000, Macrogol 4000, polyethylene glycol 6000, Sorbitan ethoxylate, polyoxyethylene fatty acid ester, polyoxyethylene aliphatic alcohol ether, Pluronic F68 etc.; Ethylene-vinyl acetate copolymer and derivant thereof are such as ethylene-vinyl acetate copolymer 14/5, ethylene-vinyl acetate copolymer 28/250, polyvinyl acetate, polyvinyl acetate phthalate etc.; Cellulose and derivant thereof are such as methylcellulose, ethyl cellulose, sodium carboxymethyl cellulose, hydroxyethyl-cellulose, hydroxyethylmethyl-cellulose, hydroxypropyl cellulose, hydroxypropyl emthylcellulose, Cellulose ethyl hydroxypropyl ether etc.; Carbopol and derivant thereof are such as carbomer 910, Acritamer 940, carbomer 934, carbomer 910, Carbopol, carbopol ester etc.Preferred compositions is polyvinylpyrrolidone and derivant and Polyethylene Glycol and derivant thereof, cellulose and derivant thereof and carbopol and derivant thereof, wherein, the hydrophilic gel that the mixture of polyvinylpyrrolidone and Polyethylene Glycol makes is better to the rasagiline permeability, polyvinylpyrrolidone: Polyethylene Glycol (W/W) is 1: 9 to 9: 1.Wherein polyvinylpyrrolidone is preferably the K90D type, and Polyethylene Glycol is preferably the PEG400 type.PVP K90 D: PEG400 (W/W) is preferably 3: 2.Select two kinds of hydrophilic polymeric matrixs, can improve the viscosity of substrate, be conducive to paster and stick on the skin better.
In another embodiment, rasagiline transdermal patch of the present invention, except containing hydrophilic polymer substrate, for release rate or the release time of controlling rasagiline, also can add at least a hydrophobic polymer, that is to say and adopt hydrophilic polymer and hydrophobic polymer composite substrate, this combination can be that hydrophilic polymer and hydrophobic polymer mix, and also can be to add the hydrophobic polymer hypothallus that one deck contains rasagiline and pharmaceutically acceptable salt thereof on the basis of hydrophilic polymer hypothallus (containing rasagiline and pharmaceutically acceptable salt thereof).Said hydrophobic polymer is selected from least a among the following material: polyacrylic resin and derivant thereof, silicone and derivant thereof.
In another embodiment, rasagiline transdermal patch of the present invention, for release rate or the release time of controlling rasagiline, can adopt in paster, to add one deck release-controlled film, especially when selected polymeric matrix is hydrophilic polymer, active substance may occurs and discharge too fast, release time is short, for the release time of prolong drug, control release rate well, can add one deck release-controlled film.Adopt viscous characteristics and the control drug release rate characteristic of the different high molecular polymers that release-controlled film can adopt according to hypothallus to decide.Available membrane material be characterized as its moist steam permeability between 100 g/ms/day to 3000 g/ms/day.Moist steam permeability (moisture vapour transmission rate, MVTR) be that material is to the index of the penetrating ability of water vapour, can be used for weighing the penetrating ability to rasagiline, the method that MVTR measures has the documents such as GB/T 16928, ASTM E96, ASTM D1653, ISO 2528 for reference.Generally MVTR is larger, better to the penetrating effect of rasagiline, but the moist steam permeability is not to be the bigger the better, because just do not have to a certain extent greatly the controlled-release effect to rasagiline, specifically can select and comprise among the following material one or more: polyurethane, polylactic acid, polyethylene, polrvinyl chloride, ethylene-vinyl acetate copolymer, the characteristics of some films see the following form 1.Preferred release-controlled film has following 3 kinds: CoTrans9702, CoTrans9728, CoTrans9701 (being Minnesota Mining and Manufacturing Company produces), and front 2 kinds is polyethylene-polyvinyl acetate release-controlled film, CoTrans9701 is the polyurethane release-controlled film.
The characteristics of the used release-controlled film of table 1
| Model | Vinyl acetate content | Thickness | The moist steam permeability |
| CoTrans9702 | 9％ | 50.8μm | 52.8g/m 2/24h |
| CoTrans9707 | 4.5％ | 50.8μm | 15.7g/m 2/24h |
| CoTrans9720 | 0％ | 76.2μm | 6.0g/m 2/24h |
| CoTrans9726 | 2％ | 50.8μm | 10.2g/m 2/24h |
| CoTrans9728 | 19％ | 50.8μm | 97.2g/m 2/24h |
| CoTrans9701 | Be polyurethane film | 51.8μm | 709g/m 2/24h |
In yet another embodiment, rasagiline transdermal patch of the present invention, for release rate or the release time of controlling rasagiline, also can adopt control release area to come controlled release to discharge, its embodiment is by adding a skim in paster substrate, has one on this film at least less than the hole of paster area, the active substance rasagiline discharges by this hole, the size in hole can decide according to the different drug release features of different polymeric matrixs, and preferred hole area and paster Area Ratio are 1: 3～8.Its membrane material of selecting is the polymer relatively low to the permeability of rasagiline, such as polyethylene film CoTrans9720, polyethylene-polyvinyl acetate film CoTrans9726 etc.
In one embodiment, adopted release-controlled film and backing layer involution to contain the paster of semi-solid bank, the factor that affects drug release is that the affinity of medicine and substrate and release-controlled film are to the permeability of medicine.
Rasagiline of the present invention and pharmaceutically acceptable salt percutaneous plaster thereof, the pH value of paster is measured with following methods: the rasagiline mesilate cubage of pressing paster, get a certain amount of paster is configured to contain rasagiline mesilate 1mg/ml with pure water solution, for the ease of making rasagiline mesilate fully stripping from paster, can first with a small amount of absolute ethyl alcohol and stirring, supersound extraction, get final product with PH instrumentation amount.Do not making between the paster, it is to get a certain amount of medicine carrying substrate is configured to contain rasagiline mesilate 1mg/ml with pure water solution that the pH value of medicine carrying substrate is measured, for the ease of making rasagiline mesilate fully stripping from substrate, can be first with a small amount of absolute ethyl alcohol and stirring, supersound extraction, the centrifuging and taking supernatant gets final product with PH instrumentation amount.Blank substrate pH value is measured and can with reference to pharmacopoeia of each country or other standards, can be measured by the amount of medicine carrying substrate.This invention discovery is in the situation that pH value is not more than 6.5, and rasagiline is stable, otherwise then very soon degraded sees Table 2.Be not more than 6.5 requirement in order to reach pH value, rasagiline mesilate in substrate preferably with salt or/and the form of ion exist.
In the embodiment of CN101032474, rasagiline has added the alkaline conditioners such as sodium hydroxide or triethanolamine in matrix system after, can exist with the form of free alkali to a great extent, thereby promote to absorb, but rasagiline has caused adverse influence to its stability with the form of free alkali under hot conditions.Even employing double-decker: one deck contains rasagiline salt, one deck contains alkaline conditioner and also can exert an influence to stability, and therefore, the size of pH value has larger impact to the stability of active substance rasagiline, such as following table 2:
Table 2, rasagiline mesilate drug content under different PH changes
As known from Table 2, when PH greater than 6.5 the time, no matter be at 60 ℃ or 40 ℃, rasagiline all has remarkable degraded after 10 days.Equal at 6.5 o'clock at pH value, rasagiline is significantly degraded after 60 ℃, 10 days; 40 ℃, the degraded of rasagiline can be accepted after 10 days.PH value obviously affects the existence form of rasagiline: the pH value of rasagiline free alkali in pure water is about 7.5 (with rasagiline 1mg/ml time measure); The pH value of rasagiline mesilate in pure water is about 5.0 (with rasagiline mesilate 1mg/ml time measure), PKa is calculated as 7.5, so when pH value was 6.5, the amount of rasagiline free alkali accounted for 10% of total amount, Theoretical Calculation conforms to substantially with experiment.In the situation that other conditions are constant, pH value is lower, and rasagiline is more stable.When rasagiline exists with the form of free alkali, R-NH-C ≡ CH key easy fracture between the alkynyl of its secondary amine group and connection, thereby caused degraded, so with regard to stability, rasagiline is difficult to stable for extended periods of time in alkaline matrix environment, when especially being in the state of free alkali, unstability is more obvious.
Rasagiline paster of the present invention, rasagiline wherein can exist with the various ways except free alkali.The different forms that exist can adopt the diverse ways preparation, as when rasagiline exists with the form of salt or the form of ion, such as rasagiline mesilate, can be dissolved in first in the organic solvents such as ethanol, propylene glycol, glycerol, then be mixed and made into paster with organic polymer substrate, short skin penetrating agent etc.When being the form of crystallite or amorphous dispersion such as rasagiline and pharmaceutical salts thereof, can adopt solvent method, rasagiline or its salt is dissolved in ethanol or the water and and polyvidone, polyvinyl alcohol mixing, obtain the amorphous dispersion of rasagiline in polyvidone or polyvinyl alcohol after volatilizing ethanol or water, then be mixed and made into paster with organic polymer substrate, short skin penetrating agent etc., polyvidone or polyvinyl alcohol are also replaceable to be that carbamide, polyethylene glycols, fiber-like etc. are as the carrier of dispersion.It should be noted that and resemble polyvidone, polyvinyl alcohol, methylcellulose in the fiber-like, the carrier that the fusing points such as ethyl cellulose are higher, what adopt during preparation is solvent method, and resemble the Macrogol 4000 of carbamide and Polyethylene Glycol apoplexy due to endogenous wind, polyethylene glycol 6000, then be to adopt the fusion method preparation, as with rasagiline with through the Macrogol 4000 mix homogeneously of refinement, be heated to 40～60 ℃ and make its fusing, make it again be converted into solid by violent reduction temperature again, obtain crystallite or the amorphous dispersing morphology of rasagiline, then with organic polymer substrate, short skin penetrating agent etc. is mixed and made into paster.Rasagiline exists with microemulsion, submicron emulsion form can use oils, such as liquid Paraffin, vaseline, long-chain fat alcohols such as hexadecanol, octadecanol etc. are as interior phase, form microemulsion, the submicron emulsion of oil-in-water structure, rasagiline and pharmaceutically acceptable salt thereof are dissolved in the oil phase, be the supersaturation attitude, because thermodynamic (al) labile state, be easy to separate out and see through skin, this microemulsion, submicron emulsion can make with high-speed mixing method, the even method of high speed breast, microemulsion, submicron emulsion and the organic polymer substrate that makes, short skin penetrating agent etc. can be mixed and made into paster.The percutaneous plaster of preparation rasagiline liposome form, available class Ester, such as lecithin, hydrolecithin, cholesterol etc., rasagiline is wrapped up, make liposome, method has membrane process, reverse phase evaporation, freeze-drying, PH-gradient method, high-speed mixing method, breast is spared method etc. at a high speed, and then the liposome of the rasagiline that makes makes paster with organic polymer substrate, short skin penetrating agent etc.The method of the rasagiline of above preparation microemulsion parcel, submicron emulsion parcel, lipid parcel all is that those of ordinary skills can realize according to existing corresponding conventional formulation technology of preparing.Which kind of no matter with method prepare, all can regulate pH value by adding the PH regulator, the pH value that guarantees paster is not more than 6.5, because paster is to pass through percutaneous drug delivery, if the too low meeting of pH value causes zest to skin, so the pH value of paster also should be not less than 3.0, therefore, the preferred pH value scope of the present invention is for being not less than 3.0 greater than 6.5.
The method of regulating PH mainly is by adding acidic materials and/or adding pH value at the buffer reagent below 6.5.Acidic materials comprise: adipic acid, caproic acid, propanoic acid, benzoic acid, phenylacetic acid, phthalic acid, formic acid, hypophosphorous acid, phosphoric acid, sodium dihydrogen phosphate, potassium dihydrogen phosphate, glacial acetic acid, acetic acid, lactic acid, malic acid, citric acid, hydrochloric acid, sulphuric acid, nitric acid, sulfonic acid, methanesulfonic acid, benzenesulfonic acid, p-methyl benzenesulfonic acid, tartaric acid, succinic acid, boric acid, sorbic acid, silicic acid etc., also comprise the pH value that will record in advance less than 6.5 substrate with greater than 6.5 mutually mixing, make the pH value of mixture be not more than 6.5; Buffer reagent comprises formates buffer, acetate buffer, phosphate buffer, citrate buffer, phthalate buffer etc., and the acidic materials of the above and buffer reagent all are that this area is commonly used, and its using method also is routine techniques.After it should be noted that the pharmaceutically acceptable salt of rasagiline such as rasagiline mesilate, hydrochloric acid rasagiline etc. join in the above-mentioned macromolecular material, because the complexity of macromolecular material makes the pH value of whole system might be less than 6.5, also might be greater than 6.5, adding pH value regulator purpose is exactly to guarantee that the pH value of paster is below 6.5 under preparation and condition of storage.
Keratodermatitis is the major obstacle that percutaneous absorbs, therefore, and some soften cuticles and strengthen the transdermal effect that the material of the lipid flowability in the skin histology can the enhanced activity composition.In patent CN101032474, mentioned the factor that affects the rasagiline transdermal effect: whether it sequentially becomes free alkali＞short penetrating agent kind for the short penetrating agent＞principal agent of substrate＞whether contain.In the embodiment 1 to 5 of patent CN101032474, used the NaOH aqueous solution to regulate pH value to 7.5, but the salt that makes rasagiline and hyoscine thereof exist with the form of rasagiline free alkali, thereby promote to absorb; In embodiment 6, triethanolamine is regulated pH value to 8.5 as regulator.So no doubt can strengthen the transdermal penetration of rasagiline, but it unstablely can not stand its practical application.In the situation that pH value is not more than 6.5, the paster take non-hydrophilic high molecular materials such as polyacrylic acid, silicone as substrate, the rasagiline permeability is excessively low.Do the rasagiline paster of medicine carrying glue-line with hydrophilic macromolecular material such as polyvinyl alcohol, polyvinylpyrrolidone, Polyethylene Glycol, ethylene-vinyl acetate copolymer, carbopol, cellulose derivative etc., can absorb skin and extraneous moisture, make it to form the saturated solution of rasagiline, promote the release of rasagiline, greatly improved the infiltration capacity of rasagiline simultaneously.The transdermal effect of the composite bed of surprisingly doing with hydrophilic high molecular material substrate and non-hydrophilic high molecular material substrate is also fine.The composite paster transdermal effect that has added release-controlled film is pretty good, and medicine moves in the experiment in vivo, and slow release effect is optimum.Come the scheme of controlled release with control drug release area, also substantially reached the controlled release releasing effect of transdermal effect and medicine.
The preparation method of rasagiline transdermal patch of the present invention is illustrated in an embodiment.The percutaneous plaster that makes uses Franz diffusion cell (Franz cell, effectively receptor area is that 2.54 square centimeters, volume are 17 milliliters), with two the monthly age rat the abdominal part skin of shedding study its penetration, can find out that rasagiline transdermal patch of the present invention can provide abundant amount to reach the purpose of general action via skin.
The percutaneous plaster of stablizing controlled rasagiline and pharmaceutically acceptable salt thereof of the present invention can every 1-3 day administration 1 time or longer time as 1 all administrations 1 time.
Description of drawings
The generalized section of Fig. 1, embodiment 1,2,3 paster.
The generalized section of the paster of Fig. 2, embodiment 4.
The generalized section of the paster of Fig. 3 embodiment 5.
The generalized section of the paster of Fig. 4 embodiment 6.
The floor map of the paster of Fig. 5 embodiment 6.
The generalized section of the paster of Fig. 6 embodiment 7.
Fig. 7 embodiment 1 paster, meta-accumulation infiltration capacity graph of relation when containing the rasagiline of single-layer polypropylene acid esters substrate paster of rasagiline.
Fig. 8 embodiment 2 pasters, meta-accumulation infiltration capacity graph of relation when containing the rasagiline of monolayer silicon ketone group matter paster of rasagiline.
Fig. 9 embodiment 3 pasters, meta-accumulation infiltration capacity graph of relation when containing the rasagiline of the monolayer polyethylene ketopyrrolidine of rasagiline-polyvinyl alcohol composite interstitial substance paster.
Figure 10 embodiment 4 pasters, contain rasagiline add the rasagiline of release-controlled film polyvinylpyrrolidone-polyvinyl alcohol composite interstitial substance paster the time meta-accumulation infiltration capacity graph of relation.
Figure 11 embodiment 5 pasters, meta-accumulation infiltration capacity graph of relation when containing the rasagiline of composite bed paster of rasagiline.
The paster of Figure 12 embodiment 7, meta-accumulation infiltration capacity graph of relation when containing the rasagiline of the paster of depot take methylcellulose-Acritamer 940 as substrate of rasagiline mesilate.
The paster of Figure 13 embodiment 2, rasagiline is blood drug level-time graph in the rabbit body.
The paster of Figure 14 embodiment 3, rasagiline is blood drug level-time graph in the rabbit body
The paster of Figure 15 embodiment 4, rasagiline is blood drug level-time graph in the rabbit body
The paster of Figure 16 embodiment 5, rasagiline is blood drug level-time graph in the rabbit body
The paster of Figure 17 embodiment 6, rasagiline is blood drug level-time graph in the rabbit body
The specific embodiment mode
Following examples are used for further specifying content of the present invention, but do not limit the scope of the invention.
Embodiment 1: contain the single-layer polypropylene acid esters substrate paster of rasagiline mesilate, take the moon oleic acid as short skin penetrating agent
Get 0.25 gram rasagiline mesilate and be dissolved in the 1 gram propylene glycol, it is joined in polyacrylic acid ester gum 20 grams (national of the United States's starch company, 387-2287 type).Add oleic acid 0.3 gram, after stirring, with automatic coating machine (the triumphant company of the Shanghai iron of fine quality, TB-04 type) with the glue-coating that mixes on siliconised paper, coating thickness is 0.6 millimeter.60 ℃ of oven dry were covered with supporting layer after 5 minutes, and are namely transferable, paster is die-cut or cut into last thin slice again.Recording rasagiline content is 220ug/cm
2, measuring PH is 4.4.The paster generalized section that makes is seen Fig. 1.
With the paster for preparing use Franz diffusion cell (Franz cell) and two the monthly age rat the abdominal part skin of shedding study its penetration.With the content of high effective liquid chromatography for measuring rasagiline in different time points, calculate accordingly again the accumulation infiltration capacity of rasagiline, the result sees the following form respectively 3; Meta-accumulation infiltration capacity graph of relation is seen Fig. 7 during rasagiline.
Meta-accumulation infiltration capacity tables of data when table 3 contains the rasagiline paster of oleic acid
| Time (h) | Accumulation infiltration capacity (μ g) |
| 0 | 0.0 |
| 1 | 0.0 |
| 2 | 0.0 |
| 4 | 0.0 |
| 6 | 1.1 |
| 8 | 9.9 |
| 12 | 20.2 |
| 24 | 41.6 |
| 48 | 74.5 |
Embodiment 2: contain the monolayer silicon ketone group matter paster of rasagiline, take laurocapram as short skin penetrating agent
Get 0.25 gram rasagiline free alkali and be dissolved in the 1 gram propylene glycol, then it is joined in silicone adhesive 20 grams (Minnesota Mining and Manufacturing Company, PSA7-4302 type).Add laurocapram 0.3 gram, after stirring, it is 7.7 that the glue that takes a morsel records pH value as sample (being used for stability study).By the preparation of above-mentioned prescription, technique, and add 0.15 gram methanesulfonic acid and stir, make glue, take a morsel glue as sample survey (being used for stability study) pH value is 4.0.With automatic coating machine (the triumphant company of the Shanghai iron of fine quality, TB-04 type) with the glue-coating that mixes on siliconised paper, coating thickness is 0.6 millimeter.60 ℃ of oven dry were covered with supporting layer after 5 minutes, and are namely transferable, paster is die-cut or cut into last thin slice again.Recording rasagiline content is 220ug/cm
2The paster generalized section that makes is seen Fig. 1.
The paster for preparing is calculated the accumulation infiltration capacity of rasagiline by the method for embodiment one, the result sees the following form respectively 4.Meta-accumulation infiltration capacity graph of relation is seen Fig. 8 during rasagiline.
Meta-accumulation infiltration capacity tables of data when table 4 contains the rasagiline paster of laurocapram
| Time (h) | Accumulation infiltration capacity (μ g) |
| 0 | 0.0 |
| 1 | 0.0 |
| 2 | 0.0 |
| 4 | 0.0 |
| 6 | 9.2 |
| 8 | 14.3 |
| 12 | 23.1 |
| 24 | 44.7 |
| 48 | 76.2 |
Can find out that from table 3 and table 4 the prepared pasters of non-hydrophilic pressure sensitive adhesive such as adopting polyacrylic acid, silicone was at the 48th hour, the accumulation infiltration capacity is all below 200 μ g, compare with the embodiment one of patent CN101032474, the accumulation infiltration capacity obviously reduces, and reason is that rasagiline has added methanesulfonic acid and become mesylate, drug loading less.In order to improve the accumulation infiltration capacity, adopting the hydrophilic pressure sensitive adhesive is that substrate is necessary.
Embodiment 3: contain the monolayer polyethylene ketopyrrolidine of rasagiline-Polyethylene Glycol composite interstitial substance paster, take laurocapram as short skin penetrating agent
Get 24 gram polyvinylpyrrolidone PVP-K90D (ISP Technologies, INC) be sprinkled in the 120 gram dehydrated alcohol, stirring makes its swelling complete, and 16 gram PEG400s (Nanjing Weir chemical industry) are joined wherein, mix, make blank glue.Get glue 15 grams that prepare, add rasagiline free alkali 1.0 grams, stir ultrasonic its dissolving that makes.Add laurocapram 0.3 gram, after stirring, recording pH value is 7.4.By above-mentioned prescription, technique preparation, and add methanesulfonic acid 0.6 gram, recording pH value is 4.7.With automatic coating machine (the triumphant company of the Shanghai iron of fine quality, TB-04 type) with the glue-coating that mixes on siliconised paper, coating thickness is 0.4 millimeter.60 ℃ of oven dry were covered with supporting layer after 5 minutes, and are namely transferable, paster is die-cut or cut into last thin slice again.The paster generalized section that makes is seen Fig. 1.
The paster for preparing is calculated the accumulation infiltration capacity of rasagiline by the method for embodiment one, the results are shown in following table 5; Meta-accumulation infiltration capacity graph of relation is seen Fig. 9 during rasagiline.
Meta-accumulation infiltration capacity tables of data when table 5 contains the rasagiline paster of laurocapram
| Time (h) | Accumulation infiltration capacity (μ g) |
| 0 | 0.0 |
| 1 | 88.9 |
| 2 | 152.6 |
| 4 | 327.8 |
| 6 | 520.6 |
| 8 | 752.7 |
| 12 | 925.7 |
| 24 | 1822.4 |
| 48 | 3178.4 |
Can find out and adopt polyvinylpyrrolidone, the prepared paster of Polyethylene Glycol composite interstitial substance pressure sensitive adhesive at the 48th hour, the accumulation infiltration capacity is more than 1500 μ g, compare with the embodiment one of patent CN101032474, the accumulation infiltration capacity is higher, and since rasagiline mesilate do not add alkali and become free state, so stability is better.
Embodiment 4: what contain rasagiline mesilate adds release-controlled film polyvinylpyrrolidone-Polyethylene Glycol composite interstitial substance paster, take laurocapram as short skin penetrating agent
Release for the controlled release rasagiline, basis at embodiment 3 (pH value is 4.7) has added one deck release-controlled film, the preparation method of paster just in the end one goes on foot compound upper release-controlled film with embodiment 3, then adds vinylpyrrolidone-Polyethylene Glycol composite interstitial substance medicine carrying self-adhesive layer.The generalized section that makes paster is seen Fig. 2.The release-controlled film that adopts has following six kinds: CoTrans9702, CoTrans9707, CoTrans9726, CoTrans9728, CoTrans9720, CoTrans9701 (being Minnesota Mining and Manufacturing Company produces), front four kinds is polyethylene-polyvinyl acetate release-controlled film, and CoTrans9720 is that polyethylene release-controlled film, CoTrans9701 are the polyurethane release-controlled film.
Use Franz diffusion cell (Franz cell) acceptable solution volume to be 17ml the paster for preparing, receptor area is 2.54cm
2, be followed successively by sample time: 2h, 4h, 6h, 8h, 16h, 24h, 48h, 72h, 96h, 120h, result see Table respectively 6,7,8,9,10 and table 11, and meta-accumulation infiltration capacity graph of relation is seen Figure 10 during rasagiline.For six kinds of prescriptions that add release-controlled film, it is positively related that their rate of release and its moist steam permeability are into, but do not have strict linear relationship (particularly vinyl acetate content has surpassed after 10%).These six kinds of release-controlled films, that the cumulative release effect is best is CoTrans9701, its moist steam permeability also is maximum.For this invention, the moist steam permeability is too little, that rasagiline discharges is too slow, burst size very little, but the moist steam permeability is not to be the bigger the better, because just do not had to a certain extent greatly the controlled-release effect of rasagiline.
Meta-accumulation infiltration capacity tables of data during the rasagiline paster of table 6 take CoTrans9702 as release-controlled film
| Time (h) | Accumulation infiltration capacity (μ g) |
| 2 | 2.4 |
| 4 | 9.0 |
| 6 | 6.9 |
| 8 | 7.0 |
| 16 | 15.9 |
| 24 | 14.4 |
| 48 | 22.2 |
| 72 | 27.8 |
| 96 | 47.0 |
| 120 | 92.00 |
Meta-accumulation infiltration capacity tables of data during the rasagiline paster of table 7 take CoTrans9707 as release-controlled film
| Time (h) | Accumulation infiltration capacity (μ g) |
| 2 | 1.6 |
| 4 | 1.5 |
| 6 | 1.9 |
| 8 | 2.5 |
| 16 | 5.1 |
| 24 | 7.4 |
| 48 | 13.6 |
| 72 | 18.0 |
| 96 | 23.9 |
| 120 | 31.8 |
Meta-accumulation infiltration capacity tables of data during the rasagiline paster of table 8 take CoTrans9720 as release-controlled film
| Time (h) | Accumulation infiltration capacity (μ g) |
| 2 | 0.4 |
| 4 | 0.6 |
| 6 | 0.8 |
| 8 | 1.0 |
| 16 | 2.1 |
| 24 | 3.0 |
| 48 | 6.9 |
| 72 | 10.3 |
| 96 | 15.8 |
| 120 | 17.7 |
Meta-accumulation infiltration capacity tables of data during the rasagiline paster of table 9 take CoTrans9726 as release-controlled film
| Time (h) | Accumulation infiltration capacity (μ g) |
| 2 | 0.6 |
| 4 | 1.0 |
| 6 | 1.4 |
| 8 | 1.74 |
| 16 | 3.7 |
| 24 | 5.3 |
| 48 | 10.0 |
| 72 | 13.7 |
| 96 | 16.4 |
| 120 | 18.9 |
Meta-accumulation infiltration capacity tables of data during the rasagiline paster of table 10 take CoTrans9728 as release-controlled film
| Time (h) | Accumulation infiltration capacity (μ g) |
| 2 | 2.9 |
| 4 | 4.9 |
| 6 | 6.5 |
| 8 | 8.0 |
| 16 | 15.6 |
| 24 | 21.2 |
| 48 | 29.4 |
| 72 | 29.1 |
| 96 | 29.9 |
| 120 | 30.4 |
Meta-accumulation infiltration capacity tables of data during the rasagiline paster of table 11 take CoTrans9701 as release-controlled film
| Time (h) | Accumulation infiltration capacity (μ g) |
| 2 | 58.5 |
| 4 | 162.9 |
| 6 | 243.4 |
| 8 | 287.0 |
| 12 | 328.3 |
| 24 | 396.8 |
| 36 | 452.0 |
| 48 | 483.4 |
| 60 | 516.2 |
Can find out, CoTrans9701 cumulative release amount is maximum, in the pharmacokinetics experiment, also can see and use CoTrans9701 can reach comparatively ideal controlled-release effect, and keep certain blood drug level in the rabbit body of mentioning in the back.Consider the release that can affect by control controlled release area and drug loading medicine, so the moist steam permeability can be chosen at 100 g/ms/day between 3000 g/ms/day.
Embodiment 5: contain the composite bed paster of rasagiline mesilate, take laurocapram as short skin penetrating agent
Ground floor: get 24 gram polyvinylpyrrolidone PVP-K90D (ISP Technologies, INC) be sprinkled in the 120 gram dehydrated alcohol, stirring makes its swelling complete, and 16 gram PEG400s (Nanjing Weir chemical industry) are joined wherein, mix, make blank glue.Get glue 15 grams that prepare, add rasagiline mesilate 1.0 grams, stir ultrasonic its dissolving that makes.Add laurocapram 0.3 gram, after stirring, surveying pH value is 6.6.By the preparation of above-mentioned prescription, technique, and add methanesulfonic acid 0.05 gram, recording pH value is 4.8, with automatic coating machine (the triumphant company of the Shanghai iron of fine quality, TB-04 type) with the glue-coating that mixes on siliconised paper, coating thickness is 0.6 millimeter.60 ℃ of oven dry were covered with supporting layer after 5 minutes, and are namely transferable.
The second layer: get 0.25 gram rasagiline mesilate and be dissolved in the 1.0 gram propylene glycol, then it is joined in silicone adhesive 20 grams (Minnesota Mining and Manufacturing Company, PSA7-4302 type).Add a large amount laurocapram 0.4 gram, after stirring, with automatic coating machine (the triumphant company of the Shanghai iron of fine quality, TB-04 type) with the glue-coating that mixes on siliconised paper, coating thickness is 0.6 millimeter.60 ℃ of oven dry were transferred on the ground floor after 5 minutes, and are paster is die-cut or cut into last thin slice again.
The paster generalized section that makes is seen Fig. 3.
The paster for preparing is calculated the accumulation infiltration capacity of rasagiline by the method for embodiment one, the results are shown in Table 12.Meta-accumulation infiltration capacity graph of relation is seen Figure 11 during rasagiline.
Meta-accumulation infiltration capacity tables of data when table 12 contains the composite bed paster of rasagiline
| Time (h) | Accumulation infiltration capacity (μ g) |
| 2 | 0.0 |
| 4 | 9.4 |
| 6 | 57.3 |
| 8 | 103.2 |
| 11 | 155.8 |
| 22 | 243.9 |
| 34 | 293.2 |
| 48 | 308.9 |
| 72 | 495.8 |
Embodiment 6: contain the control release area paster of rasagiline mesilate, with the short skin penetrating agent of laurocapram
Get 24 gram polyvinylpyrrolidone PVP-K90D (ISP Techno logies, INC) be sprinkled in the 120 gram dehydrated alcohol, stirring makes its swelling complete, and 16 gram PEG400s (Nanjing Weir chemical industry) are joined wherein, mix, make blank glue.Get glue 15 grams that prepare, add rasagiline mesilate 1.0 grams, stir ultrasonic its dissolving that makes.Add laurocapram 0.3 gram, after stirring, recording pH value is 5.9.This embodiment compares with the pH value that embodiment 5 records before adding methanesulfonic acid, reduces to some extent, meets PH and is not more than 6.5 requirement, and this difference mainly is because the difference of polyvinylpyrrolidone, PEG400 macromolecular material is caused.With automatic coating machine (the triumphant company of the Shanghai iron of fine quality, TB-04 type) with the glue-coating that mixes on siliconised paper, coating thickness is 0.6 millimeter.60 ℃ of oven dry were covered with supporting layer after 5 minutes, and are namely transferable, pertusate CoTrans9720 thin film in the middle of again paster being covered with, and hole area and paster Area Ratio are 1: 5.The paster generalized section that makes sees that Fig. 4, plane graph see Fig. 5.Because used prescription, technique are consistent with embodiment 3, verify so directly do pharmacokinetics.
Embodiment 7: contain the paster of depot take methylcellulose-Acritamer 940 as substrate of rasagiline mesilate, take laurocapram as short skin penetrating agent
The first step: get 2 gram methylcellulose and be sprinkled in the 100 gram cold water that contain ethanol 30% (W/V), stirring makes its swelling complete, and recording pH value is 8.0,1 gram Acritamer 940 is joined wherein, mix, then leave standstill and make its swelling complete, recording pH value is 5.5, makes blank glue.Get glue 15 grams that prepare, add rasagiline mesilate 1.0 grams, stir ultrasonic its dissolving that makes.Add laurocapram 0.3 gram, after stirring, make pastille glue.Surveying pH value is 5.0.
Second one: get CoTrans9720 film and CoTrans97201 film, the pouch of the 2cm*2cm of the synthetic openings at one side of heat-sealing adds such as 0.25 gram pastille glue in bag, with the opening edge heat sealing, makes paster.
The paster generalized section that makes is seen Fig. 6.
The paster for preparing is calculated the accumulation infiltration capacity of rasagiline by the method for embodiment one, the results are shown in Table 13.Meta-accumulation infiltration capacity graph of relation is seen Figure 12 during rasagiline.
Table 13 contains the time meta-accumulation infiltration capacity tables of data of the Reservoir patch of rasagiline mesilate
| Time (h) | Accumulation infiltration capacity (μ g) |
| 2 | 0 |
| 4 | 9.1 |
| 6 | 51.3 |
| 8 | 92 |
| 11 | 136.4 |
| 22 | 219.7 |
| 34 | 275.5 |
| 48 | 314.4 |
| 72 | 383.2 |
Therefore, according to paster of the present invention, use different substrate and technique approximately the paster of 4～10 square centimeters of sizes can absorb through skin and reach 1～3 day required therapeutic dose, and can control the infiltration rate of rasagiline by the mode of preparation multiple-layered patches, because this dosing paster material source is extensive, be easy to get, and be easy to make, and can transmit rasagiline to skin via whole stromal surface and absorb, with respect to US2004013620 and described in system have preparation method simple, raw material sources extensively are easy to get, release is milder, drug release time is longer, wait advantage more fully via the skin absorbtivity.Compare with CN101032474, drug release time is longer, more stable, more environmental protection of preparation process, safety.
Among above seven embodiment, embodiment 1,2,3,5,6,7 has all related to the impact (embodiment 4 on the basis of embodiment 3 added release-controlled film) of pH value on rasagiline stability, the inventor has investigated under the different PH condition, rasagiline is in 40 ℃ of placement variations after 10 days, result such as following table 14.Data show, when pH value less than 6.5 the time, it is stable that the rasagiline in the paster keeps, and is conducive to long-term all depositing, and PH is greater than 6.5 o'clock, the rasagiline in the paster is unstable, is unfavorable for long-term storage.
Above seven embodiment, choose wherein 5 and carry out the body giving drugs into nose for dynamics research:
Reference examples: rasagiline mesilate sheet, dosage are 1.0mg/.
Embodiment 2: contain the monolayer silicon ketone group matter paster of rasagiline, take laurocapram as short skin penetrating agent, dosage is 0.503mg/.
Embodiment 3: contain the monolayer polyethylene ketopyrrolidine of rasagiline-polyvinyl alcohol composite interstitial substance paster, take laurocapram as short skin penetrating agent, dosage 3.3mg/ only.
Embodiment 4: contain the polyvinylpyrrolidone that adds the Cotrans9701 release-controlled film of rasagiline-polyvinyl alcohol composite interstitial substance paster, take laurocapram as short skin penetrating agent, dosage be 13.2mg/ only.
Embodiment 5: contain the composite bed paster of rasagiline mesilate, take laurocapram as short skin penetrating agent, dosage is 8mg/.
Embodiment 6: contain the control release area paster of rasagiline mesilate, with the short skin penetrating agent of laurocapram, dosage is 8.4mg/.
Experimental subject is New Zealand's large ear rabbit, and body weight 1.5kg～2kg adopts high performance liquid chromatogram-GC-MS (U.S. Agilent company, Agilent1200,6410 Triple Quad LC/MS) to monitor the blood drug level of different time.
That measures the results are shown in following table 15, and blood drug level-time plot is seen Figure 13 in the body.
According to table 5, table 12-13, the data of table 14 and table 15, transdermal of the present invention pastes and has not only kept good transdermal effect, has overcome unsettled shortcoming, and blood drug level is also very desirable, and controlled-release effect is obvious, is better than oral formulations.
Among table 14 embodiment, pH value is on the impact of rasagiline stability
Table 15 drug disposition dynamic metabolism is measured
Claims (14)
1. the rasagiline transdermal patch of a stable capable of realizing controlled-release release comprises: the rasagiline of a effective dose and pharmaceutically acceptable salt thereof, and at least a hydrophilic polymer substrate of b, the pH value of this paster of c is not more than between 6.5 being not less than 3.0.
2. rasagiline transdermal patch according to claim 1, rasagiline wherein comprises hydrochlorate, mesylate, tosilate, benzene sulfonate or sulfate at pharmaceutically acceptable salt.
3. rasagiline transdermal patch according to claim 1, described hydrophilic polymer substrate is selected from a kind of in the following material or two kinds: polyvinylpyrrolidone, Polyethylene Glycol, ethylene-vinyl acetate copolymer, cellulose and carbopol.
4. according to claim 1 to 3 arbitrary described rasagiline transdermal patch, also further comprise at least a hydrophobic polymeric matrix, said hydrophobic polymer substrate is polyacrylic resin or silicone.
5. according to claim 1 to 3 arbitrary described rasagiline transdermal patch, further comprise one deck release-controlled film, the moist steam permeability that it is characterized in that membrane material is 100 g/ms/day to 3000 g/ms/day.
6. rasagiline transdermal patch according to claim 5, said membrane material are selected from least a in the following material: polyethylene, ethylene-vinyl acetate copolymer, polyurethane and polrvinyl chloride.
7. according to claim 1 to 3 arbitrary described rasagiline transdermal patch, also further comprise a skim, this film has one at least less than the hole of paster area.
8. rasagiline transdermal patch according to claim 1 also comprises a kind of pH adjusting agent.
9. rasagiline transdermal patch according to claim 1 also comprises a kind of buffer.
10. rasagiline transdermal patch according to claim 8, said pH adjusting agent is selected from least a material in the following acidic materials: adipic acid, caproic acid, propanoic acid, benzoic acid, phenylacetic acid, phthalic acid, formic acid, phosphoric acid, sodium dihydrogen phosphate, potassium dihydrogen phosphate, acetic acid, lactic acid, malic acid, citric acid, hydrochloric acid, sulphuric acid, sulfonic acid, methanesulfonic acid, tartaric acid, succinic acid, boric acid, sorbic acid and p-methyl benzenesulfonic acid.
11. rasagiline transdermal patch according to claim 10, described pH adjusting agent are hydrochloric acid, methanesulfonic acid or p-methyl benzenesulfonic acid.
12. rasagiline transdermal patch according to claim 9, wherein, described buffer is selected from least a in the following solution: formates buffer, acetate buffer, phosphate buffer, citrate buffer and phthalate buffer.
13. rasagiline transdermal patch according to claim 1 also comprises at least a transdermal enhancer.
14. rasagiline transdermal patch according to claim 13, said transdermal enhancer are selected from least a in the following material: ethanol, propylene glycol, oleic acid, oleyl alcohol, linoleic acid, lauryl alcohol, lauric acid, isopropyl myristate and laurocapram.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100698501A CN101606923B (en) | 2008-06-20 | 2008-06-20 | Stable controlled-release rasagiline transdermal patch and preparation method thereof |
| PCT/CN2009/072352 WO2009152777A1 (en) | 2008-06-20 | 2009-06-19 | A stable and release-controlled rasagiline transdermal patch and method of preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100698501A CN101606923B (en) | 2008-06-20 | 2008-06-20 | Stable controlled-release rasagiline transdermal patch and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101606923A CN101606923A (en) | 2009-12-23 |
| CN101606923B true CN101606923B (en) | 2013-01-09 |
Family
ID=41433714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100698501A Active CN101606923B (en) | 2008-06-20 | 2008-06-20 | Stable controlled-release rasagiline transdermal patch and preparation method thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101606923B (en) |
| WO (1) | WO2009152777A1 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8809310B2 (en) | 2006-02-21 | 2014-08-19 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| WO2007117431A2 (en) | 2006-04-03 | 2007-10-18 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of restless legs syndrome |
| US8188149B2 (en) | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| JP2011524907A (en) | 2008-06-19 | 2011-09-08 | テバ ファーマシューティカル インダストリーズ リミティド | Process for preparing and drying solid rasagiline base |
| US20100189791A1 (en) | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
| CN102048717B (en) | 2009-10-29 | 2014-02-19 | 重庆医药工业研究院有限责任公司 | Stable rasagiline composition |
| UA103851C2 (en) * | 2010-04-30 | 2013-11-25 | ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. | Propylaminoindan transdermal composition |
| CN102475692A (en) * | 2010-11-29 | 2012-05-30 | 重庆医药工业研究院有限责任公司 | Transdermal patch preventing rasagiline from volatilizing |
| WO2012129429A2 (en) | 2011-03-24 | 2012-09-27 | Teikoku Pharma Usa, Inc. | Transdermal compositions comprising an active agent layer and an active agent conversion layer |
| JP5913614B2 (en) | 2011-11-09 | 2016-04-27 | テイコク ファーマ ユーエスエー インコーポレーテッド | Method for treating skin neoplasm |
| WO2014070622A1 (en) | 2012-11-02 | 2014-05-08 | Teikoku Pharma Usa, Inc. | Propynylaminoindan transdermal compositions |
| CN103315983B (en) * | 2012-12-20 | 2015-06-03 | 上海中西制药有限公司 | Rasagiline preparation and preparation method thereof |
| CN104510628A (en) * | 2013-09-27 | 2015-04-15 | 金红叶纸业集团有限公司 | Household paper |
| CN116077419B (en) * | 2023-02-24 | 2023-10-27 | 丽珠集团新北江制药股份有限公司 | Selaginella hydrochloride Ji Lantou skin absorbent for dogs and preparation method thereof |
| CN116036055A (en) * | 2023-03-16 | 2023-05-02 | 上海世领制药有限公司 | Transdermal patch containing rasagiline mesylate and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7150881B2 (en) * | 1997-06-26 | 2006-12-19 | Mylan Technologies, Inc. | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
| CN101032474B (en) * | 2006-03-06 | 2011-02-16 | 重庆医药工业研究院有限责任公司 | Rasagiline transparent patch for curing and preventing neurological diseases and the preparing method thereof |
| ES2375761T3 (en) * | 2006-12-14 | 2012-03-06 | Teva Pharmaceutical Industries Ltd. | SOLID CRYSTALLINE RASAGILINE BASE. |
-
2008
- 2008-06-20 CN CN2008100698501A patent/CN101606923B/en active Active
-
2009
- 2009-06-19 WO PCT/CN2009/072352 patent/WO2009152777A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CN101606923A (en) | 2009-12-23 |
| WO2009152777A1 (en) | 2009-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101606923B (en) | Stable controlled-release rasagiline transdermal patch and preparation method thereof | |
| CN101032474B (en) | Rasagiline transparent patch for curing and preventing neurological diseases and the preparing method thereof | |
| US9486417B2 (en) | Transdermal therapeutic system for administering lipophilic and/or sparingly skin-permeable active substances | |
| US8071125B2 (en) | Transdermal patch containing isosorbide dinitrate and bisoprolol | |
| KR100764679B1 (en) | Patches comprising paroxetine for transdermal application | |
| KR20150036478A (en) | Adhesive patch | |
| TW201229170A (en) | Donepezil transdermal patch | |
| NO330805B1 (en) | Use of an anagrelide agent and transdermal pharmaceutical composition comprising such agent | |
| CN110638792B (en) | Rotigotine percutaneous absorption patch and preparation and application thereof | |
| CN102048717B (en) | Stable rasagiline composition | |
| CN101977598B (en) | Water-based adhesive skin patch comprising ketoprofen lysine salt | |
| EP1865931B1 (en) | Transdermal patch | |
| JPS6310716A (en) | Beta-stimulation agent for external use | |
| CN101637476B (en) | Preparation for percutaneous administration and preparation method and application thereof | |
| CN115475152A (en) | External preparation of flurbiprofen and preparation method thereof | |
| JP2009137925A (en) | Percutaneous absorption tape preparation and method for producing the same | |
| US8568770B2 (en) | Adhesive material containing 5-methyl-1-phenyl-2-(1H)-pyridone | |
| CN111000834B (en) | Amxitin pharmaceutical composition, amxitin patch and preparation method and application thereof | |
| WO2018005593A1 (en) | Transdermal delivery system containing methylphenidate or its salts and methods thereof | |
| JPH11228414A (en) | Tandspirone agent for percutaneous administration | |
| CN104983723A (en) | External application patch containing enalapril and application thereof | |
| US20110223236A1 (en) | Selegiline-containing adhesive preparation | |
| WO2017057541A1 (en) | Transdermal absorption preparation | |
| JP2764183B2 (en) | Medical patch | |
| CN100459977C (en) | Skin penetrating paste of indomethacin albuterol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |